Hillsborough, CA, United States of America

Bruce Alan Keyt

USPTO Granted Patents = 41 (Patent Applications = 31)

CIPO Patents = 5 (Patent Applications = 13)

EPO Patents = 17 (Patent Applications = 29)

Average Co-Inventor Count = 5.0

ph-index = 12

Forward Citations = 395(Granted Patents)

Company Filing History:

18 out of 20

Igm Biosciences, Inc.

Trellis Bioscience, Inc.

Trellis Rsv Holdings, Inc.

where one patent can have more than one assignee

Years Active: 2008-2023

Loading Chart...

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11639389 - Binding molecules with modified J-chain (2023-05-02),

2. 11578131 - Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules (2023-02-14),

3. 11555075 - Modified J-chain (2023-01-17),

4. 11542342 - Binding molecules with modified J-chain (2023-01-03),

5. 11535664 - Multi-valent hepatitis B virus antigen binding molecules and uses thereof (2022-12-27),

6. 11492411 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2022-11-08),

7. 11192941 - Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof (2021-12-07),

8. 10975147 - Modified J-chain (2021-04-13),

9. 10954302 - Anti-PD-L1 antibodies (2021-03-23),

10. 10899835 - IgM Fc and J-chain mutations that affect IgM serum half-life (2021-01-26),

11. 10822399 - IgA multi-specific binding molecules (2020-11-03),

12. 10787520 - Multimeric bispecific binding molecules specific for CD20 and CD3 (2020-09-29),

13. 10689449 - Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof (2020-06-23),

14. 10618978 - Binding molecules with modified J-chain (2020-04-14),

15. 10604559 - Multi-valent hepatitis B virus antigen binding molecules and uses thereof (2020-03-31),

Title: Innovations and Contributions of Bruce Alan Keyt

Introduction

Bruce Alan Keyt, an esteemed inventor based in Hillsborough, CA, has made significant contributions to the field of biotechnology through his extensive research and development efforts. With an impressive portfolio of 41 patents, Keyt has established himself as a leading figure in the creation of innovative solutions that advance medical science.

Latest Patents

Among his latest inventions are critical advancements in antibody technology and apoptosis. One notable patent involves binding molecules that include antibodies with a modified J-chain designed to antagonize a T-cell inhibitory signaling pathway, enhancing therapeutic applications in immunology. Another groundbreaking patent discloses polynucleotides encoding binding molecules for Tumor Necrosis Factor (TNF) superfamily receptors. This innovation enables the targeted killing of TNF receptor-expressing cells, presenting a vital approach in cancer treatment.

Career Highlights

Throughout his career, Bruce Alan Keyt has worked with several prestigious companies that focus on cutting-edge biotechnology. He has been associated with IgM Biosciences, Inc. and Amgen Fremont Inc., where his expertise in antibody and receptor technology has contributed to significant advancements in therapeutic development.

Collaborations

Keyt's innovations are not achieved in isolation, as he has collaborated with talented professionals in the field. Notable coworkers include Orit Foord and Ramesh Baliga, with whom he has worked on various projects that harness the power of antibody engineering and targeted therapies.

Conclusion

Bruce Alan Keyt continues to be a pivotal figure in the realm of patentable innovations. His numerous patents underscore his commitment to advancing biotechnological solutions that could potentially transform therapeutic options in medicine. As his research progresses, the impact of his inventions will undoubtedly contribute to the betterment of human health and disease management.

This text is generated by artificial intelligence and may not be accurate.